KemPharm to Present Data at PAINWeek 2016
September 08 2016 - 7:30AM
KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty
pharmaceutical company focused on the discovery and development of
proprietary prodrugs, today announced it will present data from two
studies involving KP201, the company’s prodrug of hydrocodone
(benzhydrocodone), at the PAINWeek 2016 Annual Meeting, September
6-10, 2016 in Las Vegas, Nevada.
The first poster to be presented,
“Pharmacokinetics and abuse potential of benzhydrocodone, a novel
prodrug of hydrocodone, after intranasal administration in
recreational drug users,” (Abstract #0716, September 8, 2016, 6:30
– 8:30 pm) provides a review of the full data package from the
KP201.A03 trial, which compared hydrocodone exposure following
insufflation of KP201 vs. hydrocodone bitartrate (HB).
In the trial, KemPharm observed that peak
hydrocodone plasma concentration (Cmax) was 36.0% lower, and total
hydrocodone exposures (AUClast and AUCinf) were 20.3% and 19.5%
lower, respectively, for intranasal (IN) KP201 compared to IN HB
(p<0.0001). Reductions in exposure were particularly apparent at
early time points after dosing, with a ≥75% reduction in
hydrocodone exposure for IN KP201 relative to IN HB at all time
intervals up to one-hour post-dose. Additionally, “Peak Drug
Liking” score, as assessed by maximal liking (Emax), was lower for
IN KP201 compared to IN HB (p=0.004), with approximately 45% of
subjects showing ≥30% reduction in Peak Drug Liking Emax compared
to HB.
The second poster presentation, “In vitro
tampering assessment of the novel prodrug combination,
benzhydrocodone/acetaminophen (Apadaz™), compared to
hydrocodone/acetaminophen,” (Abstract #0733, September 8, 2016,
6:30 – 8:30 pm) provides an analysis of extraction studies designed
to evaluate the tamper-resistant properties of Apadaz, KemPharm's
prodrug of hydrocodone in combination with acetaminophen (APAP),
compared to a generic HB/APAP product (HB/APAP).
Collectively, the data concluded that Apadaz provides
physicochemical barriers that may make manipulation for IN and
intravenous abuse inefficient and difficult compared to currently
available IR hydrocodone combination products.
In large volume extraction experiments under
non-stressing conditions, less than 5% of hydrocodone was released
from Apadaz in 23 of 26 solvents. The maximum amount of hydrocodone
that could be extracted was 37%, accomplished with an extremely
acidic solvent after six hours. In contrast, 85% of hydrocodone
could be extracted from HB/APAP with common ingestible solvents
within 5 minutes. In small volume extraction experiments, no
hydrocodone was released above the limit of quantitation from
Apadaz under any of the 164 test conditions, whereas all 164
conditions released hydrocodone from HB/APAP.
“As we advance KP201/IR, our immediate-release,
acetaminophen-free formulation of KP201, toward an Investigational
New Drug application filing, the studies presented during PAINWeek
2016 demonstrate properties of our hydrocodone prodrug that we
believe illustrate the potential of this product candidate to deter
misuse, diversion and abuse,” stated Travis C. Mickle, Ph.D.,
President and Chief Executive Officer of KemPharm. “We are
appreciative of the opportunity to present this data at PAINWeek
and look forward to continuing the clinical development of
KP201/IR.”
About KemPharm
KemPharm is a clinical-stage specialty
pharmaceutical company focused on the discovery and development of
proprietary prodrugs to treat serious medical conditions through
its LAT platform technology. KemPharm utilizes its LAT
platform technology to generate improved prodrug versions of
FDA-approved drugs in the high need areas of pain, ADHD and other
CNS disorders.
Caution Concerning Forward Looking
StatementsThis press release may contain forward-looking
statements made in reliance upon the safe harbor provisions of
Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Securities Exchange Act of 1934, as amended.
Forward-looking statements include all statements that do not
relate solely to historical or current facts, and can be identified
by the use of words such as “may,” “will,” “expect,” “project,”
“estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,”
“continue” or the negative versions of those words or other
comparable words. These forward-looking statements include
statements regarding the expected features and characteristics of
KP201/IR and Apadaz™, and the expected timing of filing of an
Investigational New Drug application for KP201/IR. These
forward-looking statements are not guarantees of future actions or
performance. These forward-looking statements are based on
information currently available to KemPharm and its current plans
or expectations, and are subject to a number of uncertainties and
risks that could significantly affect current plans. Actual results
and performance could differ materially from those projected in the
forward-looking statements as a result of many factors, including,
without limitation, the risks and uncertainties associated with:
KemPharm's financial resources and whether they will be sufficient
to meet KemPharm's business objectives and operational
requirements; results of earlier studies and trials may not be
predictive of future clinical trial results; the protection and
market exclusivity provided by KemPharm's intellectual property;
risks related to the drug discovery and the regulatory approval
process; the impact of competitive products and technological
changes; and the FDA approval process under the Section 505(b)(2)
regulatory pathway, including without limitation any timelines for
related approval. KemPharm's forward-looking statements also
involve assumptions that, if they prove incorrect, would cause its
results to differ materially from those expressed or implied by
such forward-looking statements. These and other risks concerning
KemPharm’s business are described in additional detail in
KemPharm's Quarterly Report on Form 10-Q for the quarter ended June
30, 2016, and KemPharm’s other Periodic and Current Reports filed
with the Securities and Exchange Commission. KemPharm is
under no obligation to (and expressly disclaims any such obligation
to) update or alter its forward-looking statements, whether as a
result of new information, future events or otherwise.
Investor Contacts:
Jason Rando / Joshua Drumm, Ph.D.
Tiberend Strategic Advisors, Inc.
212-375-2665 / 2664
jrando@tiberend.com
jdrumm@tiberend.com
Media Contact:
Daniel L. Cohen
Executive VP, Government and Public Relations
KemPharm, Inc.
202-329-1825
dcohen@kempharm.com
KemPharm (NASDAQ:KMPH)
Historical Stock Chart
From Mar 2024 to Apr 2024
KemPharm (NASDAQ:KMPH)
Historical Stock Chart
From Apr 2023 to Apr 2024